Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Recovery from Mouse Hepatitis Virus Infection Depends on Recruitment of Intrahepatic CD8\(^+\) Cells Rather Than Activation of Intrahepatic CD4\(^+\)\(\alpha\beta^-\)TCR\(_{\text{inter}}\) or NK-T Cells

Lucie Lamontagne, Suzanne Lusignan, and Christian Page

Département des Sciences Biologiques, Université du Québec à Montréal, Montréal H3C 3P8, Canada

Mouse hepatitis virus (MHV) provides an excellent animal model for the study of the immunopathological mechanisms involved in hepatic viral diseases. We previously generated an attenuated viral variant, YAC-MHV3, which induces a subclinical disease and recovery within 15 days. In contrast, the L2-MHV3 strain induces the development of a fulminant hepatitis, leading to death within 3 days. In this paper, we document intrahepatic and splenic T cell subpopulations involved in the hepatitis process and viral elimination identified in attenuated or pathogenic MHV3-infected C57BL/6 mice. Percentages of intrahepatic CD4\(^+\) cells decreased in attenuated YAC-MHV3-infected mice, while they increased in mice infected with pathogenic L2-MHV3, compared with uninfected animals. Moreover, in YAC-MHV3-infected mice, the percentages of intrahepatic CD8\(^+\) cells slightly decreased at 24 h pi, then increased until 15 days pi. In contrast, the CD4/CD8 ratios of splenic lymphoid subpopulations increased in the first days of infection and returned to normal values at 15 days pi. Intrahepatic NK1.1\(^+\)\(\alpha\beta^-\) – TCR\(_{\text{inter}}\) cells decreased in both virally infected groups of mice, while CD4\(^+\)\(\alpha\beta^-\) – TCR\(_{\text{inter}}\) LFA-1\(^{\text{high}}\) cells increased in L2-MHV3-infected mice, in contrast with what was seen in YAC-MHV3-infected mice. However, these cells became anergic following Con A or PHA stimulation. Ex vivo studies showed that only the intrahepatic CD8\(^+\) cells that were increased in YAC-MHV3-infected mice could be stimulated by lectins. In addition, in vitro viral infections revealed that L2-MHV3 viral infection led to an increase of intrahepatic CD4\(^+\)\(\alpha\beta^-\) – TCR\(_{\text{inter}}\) cells in the absence of CD8\(^+\) cells only. These results indicate that the attenuated phenotype of the YAC-MHV3 virus is related to two different mechanisms: the first involves no increase of intrahepatic CD4\(^+\)\(\alpha\beta^-\) – TCR\(_{\text{inter}}\) or NK-T cells, while the second favors the recruitment and activation of CD8\(^+\) cells in liver. The results are discussed in relation to the integrity of intrahepatic immune tolerance mechanisms and immune-mediated viral elimination.

Key Words: MHV3; coronavirus; hepatitis; T lymphocytes; liver; suppression.

INTRODUCTION

Hepatitis is an inflammatory disease induced by various causes, one of which is viral infection, in which T lymphocytes have been assumed to play an essential role in the host’s immune response to tissue injury and elimination of viral infection (1–3). The incapacity of the host to eliminate the viral infection favors the development of acute or chronic hepatitis, such as that seen in human viral hepatitides B and C (4, 5). However, the roles of specific intrahepatic lymphoid subsets involved simultaneously in the immune responses against viral infection and in the intrahepatic immune tolerance may disturb the efficiency of immune-mediated viral elimination mechanisms in decreasing the intensity of the T-cell-mediated immune pathway (5).

Mouse hepatitis virus (MHV) infection provides an excellent animal model for the study of immune-mediated mechanisms involved in intrahepatic viral elimination. MHV3 is the most hepatotropic serotype, and the liver is the main target organ for viral replication in the susceptible C57BL/6 mouse (6, 7). The pathogenic L2-MHV3-infected mice develop an acute hepatitis and die within 3 days. Within this time, progressive necrotic lesions can be observed in the liver, inducing dysfunction due to extensive necrosis (7). Simultaneously, immune disorders occur in various lymphoid organs, leading to cellular and humoral immunodeficiencies (7–10). We have previously generated a viral variant, YAC-MHV3, which induces a subclinical infection involving few hepatic cellular lesions in C57BL/6 mice, with viral clearance occurring within 15 days postinfection (pi) (8, 11). YAC-MHV3 does not induce any immunodeficiency, such as those observed with pathogenic L2-MHV3 in C57BL/6 infected mice (8–10). However, mechanisms involved in the attenuated liver pathogenicity of this variant have not yet been elucidated.
The hepatic sinusoids of normal adult mice contain \( \alpha \beta - TCR \) (T cell receptor) cells which appear to be distinct from the T cells found in peripheral lymphoid tissues (12-14). These T cells are characterized by an \( \alpha \beta - TCR \) of intermediate intensity (\( \alpha \beta - TCR^\text{inter} \)) and consist of double negative CD4\textsuperscript{−}CD8\textsuperscript{−} and single positive CD4\textsuperscript{+} or CD8\textsuperscript{+} cells (13, 14). The percentage of single-positive CD4\textsuperscript{+} cells is reported to be higher in the liver than in the spleen or thymus (14, 15). Moreover, these lymphocytes express a higher level of leucocyte function antigen-1 (LFA-1) (14), while some of them express the L-2R\( \beta \) and PgP-1 (CD44) cell surface markers normally found on antigen-experienced T cells (12, 13, 16). Some other \( \alpha \beta - TCR^\text{inter} \) cell subsets express natural killer (NK)1.1 molecules and are defined as NK-T cells (17). The protective role of these intrahepatic T cell subsets is contradictory. It has been demonstrated that intrahepatic \( \alpha \beta - TCR^\text{inter} \) cells account for a protective mechanism in hepatic resistance to the early phase of murine salmonellosis (18). In contrast, down-regulation of CD4\textsuperscript{+} \( \alpha \beta - TCR^\text{inter} \) cells favors the development of a protective immunity against listeriosis, and bacterial clearance has thus been mediated by cytotoxic CD8\textsuperscript{+} cells (19, 20). No information is available on the protective role of these cells in viral hepatitis.

We have previously observed that infection of susceptible C57BL/6 mice with the pathogenic L2-MHV3 strain induced an increase in the total number of intrahepatic mononuclear cells (MNC) and in the CD4/CD8 ratio during acute hepatitis (21). Moreover, the hepatic \( \alpha \beta - TCR^\text{inter}LFA-1^{\text{high}} \) and \( \alpha \beta - TCR^\text{high}LFA-1^{\text{high}} \) cells increased. Studies with activation markers suggest that hepatic \( \alpha \beta - TCR^\text{inter}LFA-1^{\text{high}} \) cells may be activated in situ during viral hepatitis but are not able to control the viral infection, suggesting that they are not protective against viral infection. Thus, the use of an attenuated virus that induces a subclinical infection without extensive hepatic lesions may be useful in elucidating the phenotype of the protective intrahepatic T cell subpopulations.

In this paper, we report on the hepatic and splenic T cell subpopulations during viral infection induced by the attenuated YAC-MHV3 variant in susceptible C57BL/6 mice. The results indicated that the attenuated phenotype of the YAC-MHV3 virus was related to two different mechanisms: the first involved the absence of intrahepatic CD4\textsuperscript{+} \( \alpha \beta - TCR^\text{inter} \) or NK-T cell activation and the second favored the recruitment and activation of CD8\textsuperscript{+} cells in liver.

**MATERIALS AND METHODS**

**Animals**

C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Prior to experimentation, the animals were tested for the presence of anti-MHV antibodies by an ELISA test using a MHV3 preparation as antigen. During experimentation, the animals were housed in a sterile atmosphere (Forma Scientific, Marietta, OH). Female mice between 8 and 12 weeks of age were used in all experiments.

**Virus**

Pathogenic MHV3 is a donor strain isolated from the liver of infected DBA2 mice and passaged two or four times into L2 cells (L2-MHV3). Attenuated MHV3 is a donor strain produced in YAC-1 cells as previously described (YAC-MHV3) (11). Viruses were passaged in L2 cells before use and their pathogenic properties were tested regularly.

In vivo viral infections. Groups of three mice were infected intraperitoneally (ip) with 1000 TCID\textsubscript{50} of pathogenic L2-MHV3 or the attenuated YAC-MHV3 variant (8). Mock-infected mice received ip a similar volume of PBS. At various times pi, mice were anesthetized with ketamine sulphate (200 mg/kg) and xylazine (10 mg/kg) by ip injection. Mice were bled by section of portal veins and aortic arteries, as described by Watanabe et al. (14). Liver and spleen were harvested following exsanguination.

**Cells**

L2 cells, a continuous mouse fibroblast cell line, were grown in Dulbecco's MEM with glutamine (2 mM), 5% fetal calf serum (FCS), and antibiotics (penicillin, 100 U/ml, and streptomycin, 100 mg/ml) (GIBCO BRL, Grand Island, NY). L2 cells were used for virus production and titrations.

Splenical lymphocytes were obtained from three mice in each experimental group. Spleens were pressed through a 70-\( \mu \)m cell strainer to obtain MNC. Prior to experimentation, the animals were tested for the presence of anti-MHV antibodies by an ELISA test using a MHV3 preparation as antigen. During experimentation, the animals were housed in a sterile atmosphere (Forma Scientific, Marietta, OH). Female mice between 8 and 12 weeks of age were used in all experiments.

**Virus**

Pathogenic MHV3 is a donor strain isolated from the liver of infected DBA2 mice and passaged two or four times into L2 cells (L2-MHV3). Attenuated MHV3 is a donor strain produced in YAC-1 cells as previously described (YAC-MHV3) (11). Viruses were passaged in L2 cells before use and their pathogenic properties were tested regularly.

In vivo viral infections. Groups of three mice were infected intraperitoneally (ip) with 1000 TCID\textsubscript{50} of pathogenic L2-MHV3 or the attenuated YAC-MHV3 variant (8). Mock-infected mice received ip a similar volume of PBS. At various times pi, mice were anesthetized with ketamine sulphate (200 mg/kg) and xylazine (10 mg/kg) by ip injection. Mice were bled by section of portal veins and aortic arteries, as described by Watanabe et al. (14). Liver and spleen were harvested following exsanguination.
ersham Pharmacia, Uppsala, Sweden) for 30 min at 1000g. MNC were collected at the interface of the 45 and 67% Percoll layers. The cells were then washed in RPMI 1640 containing 20% FCS and electronically counted as described above.

Depletion of CD8+ cells in hepatic and splenic cells was done by incubation of cells with anti-CD8 antibodies (monoclonal antibody (mAb) 53-6.7, Pharmingen, San Diego, CA) and guinea pig complement (Cedarlane). Residual cells were phenotyped 24 h later, as described below.

**In vitro Viral Infections**

MNC were isolated from livers originating from groups of 6 to 10 mice, as described above, and pooled together. Cells were seeded in 24-well plates at a concentration of 10^6 cells/ml and infected with 0.01 to 1 m.o.i. of L2-MHV3 or YAC-MHV3 viruses. The plates were incubated at 37°C under a CO2 atmosphere for 24 h, and cells in the supernatants were collected, electronically counted, and immunolabeled for cytofluorometric studies.

**Virus Titration**

Livers from infected mice were collected in RPMI 1640, frozen at −70°C, thawed, and then centrifuged, with the supernatants used as viral suspensions. These were then serially diluted in 10-fold steps in Dulbecco’s MEM and tested on L2 cells cultured in 96-well microtiter plates. Cytopathic effects, characterized by syncytia formation and cell lysis, were recorded at 72 h pi and virus titers expressed as log_{10} TCID_{50}. All titrations were performed in triplicate.

**Double Immunolabelings**

T cell subpopulations were labeled with the following mAb: fluorescein isothiocyanate-conjugated (FITC)-anti-CD4 (mAb RM45, Pharmingen), phycoerythrine-conjugated (PEC)-anti-CD8a (mAb S3-6.7, Pharmingen), PEC-NK.1.1 (clone PK-136, Pharmingen), FITC- or PEC-anti-LFA-1 (clone H57-597, Pharmingen), FITC- or PEC-B220 (clone RA3-6B2, Pharmingen) and PEC-anti-CD44 (clone IM7, Pharmingen). Cell suspensions were prepared from the spleen, and 10^6 cells were incubated with an optimal concentration of mAb for 30 min at 4°C, washed in PBS containing 20% FCS, and fixed overnight at 4°C in PBS, pH 7.2, containing 1% formaldehyde (Fisher Scientific). Hepatic MNC were isolated and 5 x 10^5 cells were incubated with an optimal concentrations of mAb, as described for splenic cells. Hepatic and splenic cells were similarly double labeled for the following markers: CD4/CD8, CD4/αβ – TCR, LFA-1/αβ – TCR, B220/αβ – TCR, and CD44/αβ – TCR. Isotype controls corresponding to each conjugated antibody was used.

Cytofluorometric analyses were performed on a FACScan (Becton-Dickinson, Mountain View, CA) cytofluorometer with Cell Quest software (Becton-Dickinson). Gating was performed according to forward scatter (FSC) versus 90°-angle scatter (SSC) parameters to select the distinct lymphoid cell populations. Ten thousand cells selected from this gate were analyzed per sample and percentages of various subpopulations were determined by multiparametric analysis. Experiments were conducted in triplicate or, in some experiments, data were recorded from a pool of three livers.

**Blastic Tranformation**

Metabolic activity of intrahepatic and splenic MNC was evaluated by the tetrazolium salt reduction test (Promega, Madison, WI). MNC were seeded at 10^4 per well (in 100-μl vol) in flat-bottom microtiter plates in RPMI 1640 containing 20% FCS, mercaptoethanol (ME), and antibiotics. Cells were treated with an optimal concentration of phytohemagglutinin A (PHA) and concanavalin A (Con A) (Sigma-Aldrich, Oakville, Ontario, Canada). After various times of incubation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS) (Promega) were added and cells were further incubated for up to 4 h. The optical density was determined by using an ELISA reader (492-nm filter) (Molecular Devices, Sunnyvale, CA). The experiments were conducted in quadruplicate.

**Statistical Analysis**

Percentages, absolute numbers, and OD were evaluated by the Student’s t test, comparing cells from infected and control mice for in vivo studies or comparing infected cells to control cells in in vitro studies. The ratios were analyzed using the Wilcoxon–Mann–Whitney U test.

**RESULTS**

**Viral Replication in Liver from Attenuated YAC-MHV3- and Pathogenic L2-MHV3-Infected C57BL/6 Mice**

We have previously demonstrated that the attenuated YAC-MHV3 variant induces a subclinical hepatitis characterized by few inflammatory foci and accompanied by perivascular infiltrates of mononuclear cells. Recovery was observed within 15 days pi (8). In order to verify the efficiency of immune-mediated elimina-
tion mechanisms of YAC-MHV3 replication, hepatic viral titers from YAC- and L2-MHV3-infected mice were compared at various times pi. In YAC-MHV3-infected mice, viral titers reached their maximum at 4 days pi ($10^{4.3} \pm 0.5$ TCID$_{50}$/ml) and decreased within 10 days pi, while viral titers reached higher levels in pathogenic L2-MHV3-infected mice until death at 3 days pi ($10^{6.8} \pm 1.2$ TCID$_{50}$/ml).

Analysis of CD4/CD8 Phenotypes of Intrahepatic and Splenic Lymphocytes in Attenuated YAC-MHV3- and Pathogenic L2-MHV3-Infected C57BL/6 Mice for 3 Days

To identify the intrahepatic T cell subsets involved in the control of viral infection in YAC-MHV3-infected mice, groups of three C57BL/6 mice were infected with the pathogenic L2-MHV3 or the attenuated YAC-MHV3 variant. Mice were sacrificed at 3 days pi, intrahepatic and splenic lymphoid cells were isolated, and the numbers of lymphoid cells per liver were determined by electronic counting. Numbers of intrahepatic mononuclear cells isolated from YAC-MHV3-infected mice ($1.40 \pm 0.21 \times 10^6$ cells/liver) were similar to those of uninfected mice ($1.38 \pm 0.18 \times 10^6$ cells/liver). Moreover, as previously observed, an increase of intrahepatic mononuclear cells was observed in L2-MHV3-infected mice ($3.22 \pm 0.45 \times 10^6$ cells/liver) ($P < 0.001$) (21). To verify if splenic and intrahepatic lymphocyte subsets are modified in pathogenic L2-MHV3-infected mice cells were isolated for 3 Days pi and double-labeled with FITC-anti-CD4 and PEC-anti-CD8 antibodies and analyzed using a FACScan cytofluorometer. Lymphoid cells were gated according to FSC/SSC parameters, and numbers of cells have been evaluated based on a total of 10,000 events recorded. Experiments were conducted in triplicate.

| Table 1 | Percentages of CD4$^+$ and CD8$^+$ Intrahepatic and Splenic T Cells from Pathogenic L2-MHV3- and Attenuated YAC-MHV3-Infected C57BL/6 Mice at 3 Days pi |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Organ   | Virus | CD4$^+$ | CD8$^+$ |
|---------|-------|---------|---------|
| Liver   | Control$^a$ | 21.8 ± 0.7 | 6.7 ± 0.7 |
|         | L2-MHV3 | 27.1 ± 2.1$^a$ | 9.0 ± 0.8$^{**}$ |
|         | Control | 18.4 ± 0.7 | 7.0 ± 1.5 |
|         | YAC-MHV3 | 14.1 ± 0.7$^a$ | 10.0 ± 1.0$^{**}$ |
| Spleen  | Control$^a$ | 15.9 ± 2.3 | 6.1 ± 2.3 |
|         | L2-MHV3 | 15.8 ± 3.5 | 4.3 ± 1.8 |
|         | Control | 18.8 ± 2.2 | 10.0 ± 2.1 |
|         | YAC-MHV3 | 16.7 ± 3.1 | 7.2 ± 1.3 |

$^a$ Intrahepatic or splenic MNC were double labeled with FITC-anti-CD4 and PEC-anti-CD8 antibodies and analyzed using a FACScan cytofluorometer. Lymphoid cells were gated according to FSC/SSC parameters, and numbers of cells have been evaluated based on a total of 10,000 events recorded. Experiments were conducted in triplicate.

To identify the intrahepatic T cell subsets involved in the control of viral infection in YAC-MHV3-infected mice, groups of three C57BL/6 mice were infected with the pathogenic L2-MHV3 or the attenuated YAC-MHV3 variant. Mice were sacrificed at 3 days pi, intrahepatic and splenic lymphoid cells were isolated, and the numbers of lymphoid cells per liver were determined by electronic counting. Numbers of intrahepatic mononuclear cells isolated from YAC-MHV3-infected mice ($1.40 \pm 0.21 \times 10^6$ cells/liver) were similar to those of uninfected mice ($1.38 \pm 0.18 \times 10^6$ cells/liver). Moreover, as previously observed, an increase of intrahepatic mononuclear cells was observed in L2-MHV3-infected mice ($3.22 \pm 0.45 \times 10^6$ cells/liver) ($P < 0.001$) (21). To verify if splenic and intrahepatic lymphocyte subsets are modified in pathogenic L2-MHV3- or attenuated YAC-MHV3-infected mice, groups depending on the presence of surface markers, such as CD4, CD8, or NK 1.1 (12, 13, 16, 17). To determine the phenotype of T cells slightly increased in both intrahepatic and splenic MNC were double labeled with FITC-anti-CD4 and PEC-anti-CD8 antibodies and analyzed using a FACScan cytofluorometer. Lymphoid cells were gated according to FSC/SSC parameters, and numbers of cells have been evaluated based on a total of 10,000 events recorded. Experiments were conducted in triplicate.

Analysis of LFA-1/αβ – TCR, CD4/αβ – TCR, and NK1.1/αβ – TCR Phenotypes of Intrahepatic and Splenic Lymphocytes in Attenuated YAC-MHV3- and Pathogenic L2-MHV3-Infected C57BL/6 Mice for 3 Days

As previously demonstrated, the intrahepatic αβ – TCR$^{inter}$ cells expressing a high level of LFA-1 (CD11a) molecules increased in L2-MHV3-infected mice (21). To determine if the increase of LFA-1 $\alpha\beta$ – TCR$^{inter}$ cells was associated with viral pathogenicity, intrahepatic lymphoid cells from attenuated YAC-MHV3- and pathogenic L2-MHV3-infected mice cells were isolated at three days pi and double-labeled with FITC-anti-CD11a and PEC-anti-αβ – TCR antibodies. As shown in Fig. 1A, intrahepatic CD11a$^+$αβ$^+$ – TCR$^{inter}$ or CD4$^+$αβ$^+$ – TCR$^{inter}$ cell percentages decreased in YAC-MHV3-infected mice ($P < 0.05$ or $P < 0.001$), while they increased in L2-MHV3-infected mice ($P < 0.001$ or $P < 0.05$). In the spleen, however, no change was detected in the $\alpha\beta$ – TCR$^{inter}$ subpopulations, while CD11a $\alpha\beta$ – TCR$^{high}$ cell percentages decreased more in L2-MHV3- than in YAC-MHV3-infected mice ($P < 0.001$) (Fig. 1B).

Intrahepatic T cell subsets expressing an intermediate level of $\alpha\beta$ – TCR may be separated in subset groups depending on the presence of surface markers, such as CD4, CD8, or NK 1.1 (12, 13, 16, 17). To determine the phenotype of $\alpha\beta$ – TCR$^{inter}$ cells in the livers of infected mice, double immunolabelings with FITC-anti-$\alpha\beta$ – TCR and PEC-anti-CD4$^+$ or anti-NK1.1 antibodies were performed on intrahepatic lymphoid cells isolated from pathogenic L2-MHV3- or YAC-MHV3-infected mice 3 days pi. As shown in Fig. 1C, intrahepatic CD4$^+$αβ$^+$ – TCR$^{inter}$ cell percentages decreased in YAC-MHV3-infected mice ($P < 0.001$), while they increased in L2-MHV3-infected mice ($P < 0.05$). In addition, CD4$^+$αβ$^+$ – TCR$^{high}$ cell percentages increased only in L2-MHV3-infected mice ($P < 0.001$). However, splenic CD4$^+$αβ$^+$ – TCR$^{high}$ or CD4$^+$αβ$^+$ – TCR$^{high}$ cell percentages decreased in L2-MHV3-infected mice ($P < 0.001$ or $P < 0.05$) (Fig. 1D).

On the other hand, percentages of intrahepatic NK1.1$^+$αβ$^+$ – TCR$^{inter}$ cells decreased in both groups of infected mice ($P < 0.001$), while NK1.1$^+$αβ$^+$ – TCR$^-$ cells were not affected (Fig. 1E). In addition, intrahepatic NK1.1$^+$αβ$^+$ – TCR$^{inter}$ cells increased only in
L2-MHV3-infected mice (P < 0.001). Splenic NK1.1<sup>αβ</sup> - TCR<sup>high</sup> cell percentages decreased in both groups of infected mice (P < 0.001) (Fig. 1F). NK1.1<sup>αβ</sup> - TCR<sup>−</sup> slightly decreased in spleen from L2-MHV3-infected mice only (P < 0.05). These results suggest that an increase of intrahepatic CD4<sup>αβ</sup> - TCR<sup>inter</sup> cells rather than a decrease of intrahepatic NK1.1<sup>αβ</sup> - TCR<sup>inter</sup> cells correlates with viral pathogenicity.

Sequential Study of the CD4/CD8 Phenotypes of Intrahepatic Lymphocytes in YAC-MHV3-Infected C57BL/6 Mice

In order to identify the sequential evolution of intrahepatic T cell subsets favoring recovery, groups of three C57BL/6 mice were infected with the attenuated YAC-MHV3 virus and sacrificed from 24 h to 25 days pi. The number of intrahepatic MNC was recorded, and T cell subpopulations were analyzed following double immunolabeling for CD4 and CD8 markers. No significant increase in the number of intrahepatic MNC was observed during the subclinical infection for up to 25 days pi. As shown in Fig. 2, percentages of CD4<sup>+</sup> cells transiently decreased in the first 48 h pi, followed by a percentage increase up to 15 days pi. However, CD8<sup>+</sup> cells slightly decreased at 24 h pi but strongly increased for up to 25 days pi. The percentage increases of single-positive CD8<sup>+</sup> cells remained higher than those of the CD4<sup>+</sup> cells. The changes in CD4<sup>+</sup> or CD8 subpopulations were evident through CD4/CD8 ratio analysis (Table 2). The intrahepatic CD4<sup>+</sup>/CD8<sup>+</sup> ratio

**FIG. 1.** Percentages of CD11a/αβ-TCR (A and B), CD4/αβ-TCR (C and D), and NK1.1/αβ-TCR (E and F) cell subsets in intrahepatic (A, C, E) and splenic (B, D, F) lymphoid cell populations, from control (), YAC-MHV3- (), and L2-MHV3-infected () C57BL/6 mice. Intrahepatic MNC were double labeled with FITC-anti-LFA-1(CD11a), FITC-anti-CD4, or FITC-anti-NK1.1 and PE-anti-αβ-TCR antibodies and analyzed using a FACSscan cytofluorometer. Lymphoid cells were gated according to FSC/SSC parameters, and the numbers of cells were evaluated based on a total of 10,000 events recorded. Results are representative of three experiments. *P < 0.001; **P < 0.05.
increased rapidly in the first 4 days pi but strongly decreased thereafter. In contrast, the CD4/CD8 ratio of splenic lymphoid subpopulations increased in the first days of infection and then returned to normal values at 15 days pi, thus indicating a longer period of CD8$^{+}$ cell stimulation in the liver than in spleen.

**TABLE 2**

| Time pi (days) | Liver | Spleen |
|---------------|-------|--------|
| 0             | $3.48 \pm 0.38^*$ | $1.70 \pm 0.25$ |
| 1             | $4.60 \pm 0.22^*$ | $2.58 \pm 0.27^*$ |
| 4             | $3.20 \pm 0.44$  | $2.36 \pm 0.18^{**}$ |
| 7             | $1.35 \pm 0.20^*$ | $2.91 \pm 0.36^*$ |
| 15            | $1.56 \pm 0.28^*$ | $1.80 \pm 0.31$  |
| 25            | $1.63 \pm 0.32^*$ | $1.86 \pm 0.28^*$ |

*Intrahepatic or splenic MNC were double labeled with FITC-anti-CD4 and PE-anti-CD8 antibodies and analyzed using a FACSscan cytometer. Lymphoid cells were gated according to FSC/SSC parameters, and numbers of cells have been evaluated based on a total of 10,000 events recorded. Experiments were conducted in triplicate.

Similarly, to verify whether the decrease of the specific intrahepatic $\alpha\beta$ – TCR$^{\text{inter}}$ or high cell subset favors a subclinical infection, MNC were isolated from the liver of groups of three YAC-MHV3-infected C57BL/6 mice and double immunolabeled with FITC-anti-$\alpha\beta$ – TCR and PEC-anti-LFA-1 antibodies. As observed in Fig. 4A, most intrahepatic $\alpha\beta$ – TCR$^{\text{inter}}$ cells from control mice expressed high levels of LFA-1 (LFA-1$^{1+}$) cells, while $\alpha\beta$ – TCR$^{\text{high}}$ cells expressed a lower level of LFA-1 (LFA-1$^{\text{low}}$) molecules. In YAC-MHV3-infected mice, $\alpha\beta$ – TCR$^{\text{inter}}$LFA-1$^{1+}$ cells transiently decreased at two days pi (Fig. 4C), while they returned to normal values thereafter (Figs. 4D–4F). On the other hand, $\alpha\beta$ – TCR$^{\text{inter}}$LFA-1$^{\text{low}}$ and $\alpha\beta$ – TCR$^{\text{high}}$LFA-1$^{\text{low}}$ cells increased in the first days pi. Also, only $\alpha\beta$ – TCR$^{\text{inter}}$LFA-1$^{\text{low}}$ cells remained higher until 15 days pi (Figs. 4B–4E). No major increase of $\alpha\beta$ – TCR$^{\text{high}}$LFA-1$^{1+}$ cells was observed in livers from infected mice.

We have previously observed that intrahepatic $\alpha\beta$ – TCR$^{\text{inter}}$ or high LFA-1$^{1+}$ cells isolated from pathogenic L2-MHV3-infected mice also expressed the CD44 (PgP-1) or CD45R (B220) activation markers (21). It is postulated that infection with the attenuated YAC-MHV3 variant does not allow the activation of $\alpha\beta$ – TCR$^{\text{inter}}$ or high cell subsets. This hypothesis was verified by double immunolabeling for these activation markers of intrahepatic lymphoid cells isolated from attenuated YAC-MHV3-infected mice. No important increase of intrahepatic CD4$^{44}$ cells.
was observed in YAC-MHV3-infected mice, except for intrahepatic CD44^ab-TCR^inter cells (5.1 ± 0.5%) (P < 0.05) when compared with control mice (3.3 ± 0.6%). While splenic CD44^ab-TCR^inter cells slightly decreased (YAC-MHV3-infected mice, 3.5 ± 1.3%; control mice, 6.3 ± 1.3%) (P < 0.05). Other than a decrease in αβ–TCR^inter^B220^+^ cells (YAC-MHV3-infected mice, 3.9 ± 0.4%; control mice, 8.9 ± 2.0%) (P < 0.001), no differences were observed in percentages of hepatic or splenic CD44^inter or B220^inter cells. In addition, no significant differences were found in intrahepatic or splenic total CD44^+ or B220^+ subsets from 3 to 25 days pi (results not shown).

Ex vivo Blastic Transformation of Intrahepatic and Splenic Lymphoid Cells from L2-MHV3- and YAC-MHV3-Infected C57BL/6 Mice

In order to verify whether intrahepatic MNC from L2-MHV3- and YAC-MHV3-infected mice were able to respond to antigenic stimulation, intrahepatic and splenic lymphoid cells were isolated from L2-MHV3- and YAC-MHV3-infected mice at 3 days pi and from YAC-MHV3-infected mice at 14 days pi. The cells were stimulated with PHA or Con A, and the level of blastic transformation was evaluated by a colorimetric method based on tetrazolium salt reduction. Results shown in Fig. 5 indicate that intrahepatic lymphoid cells isolated from L2-MHV3-infected mice were totally anergic 3 days pi, while those from YAC-MHV3-infected mice were less activated than cells from uninfected mice (Fig. 5A) (P < 0.001). At 14 days pi, cell activation by Con A or PHA was greater in intrahepatic lymphoid cells of YAC-MHV3-infected mice than in those of the control group (Fig. 5A) (P < 0.001). However, splenic lymphoid cells from YAC-MHV3- or L2-MHV3-infected mice at 3 or 14 days retained their ability to respond to Con A and PHA stimulation, but activation levels of splenic cells were higher in cells from YAC-MHV3-infected mice at three days pi (P < 0.001 and P < 0.05) (Fig. 5B).
Phenotype of Inactivated Intrahepatic T Cell Subset in YAC-MHV3- or L2-MHV3-Infected Mice

To determine the phenotype of partially or totally anergized intrahepatic lymphoid cells of YAC-MHV3- and L2-MHV3-infected mice, respectively, lymphoid cells were isolated from the liver and spleen of both groups of virus-infected mice at 3 days pi. Subsequently, CD8\(^+\) cells were depleted by cytotoxicity using anti-CD8 antibodies and complement. CD4/CD8 double immunolabeling of residual cells revealed that less than 1.66 \(\pm\) 0.03% expressed the CD8 marker. Cells were then cultured for 71 h, and the metabolic activity of residual T cells was evaluated by reduction levels of tetrazolium salts. As shown in Fig. 6A, metabolic activity of intrahepatic T cells from control mice partially decreased when CD8\(^+\) T cells were removed (P < 0.05). However, the decrease was exacerbated in CD8-depleted intrahepatic cells from YAC-MHV3-infected mice (P < 0.001) (Fig. 6B). In addition, metabolic activities of intrahepatic lymphoid cells before and after CD8 depletion were depressed in L2-MHV3-infected mice (P < 0.001) (Fig. 6C). However, such decreases after removal of CD8\(^+\) cells were less evident in splenic cells isolated from both groups of infected mice (Figs. 6D–6F). These results indicate that CD8\(^+\) cell subsets contributed mainly to the metabolic activity of total intrahepatic lymphoid cells isolated from YAC-MHV3-infected mice. Hence, only CD4\(^+\) cell subsets were anergized in YAC-MHV3-infected mice, while both CD8\(^+\) and CD4\(^+\) subsets were anergized in L2-MHV3-infected mice.

Modulation of Intrahepatic CD4\(^+\) Cell Subsets by in Vitro L2-MHV3 and YAC-MHV3

To determine the role of viral infection in the modulation of intrahepatic CD4 subsets, as observed in L2-MHV3- and YAC-MHV3-infected mice, intrahepatic lymphoid cells were isolated and infected in vitro with both viruses for 24 h. CD4 subsets were discriminated by a double immunolabeling with FITC-anti-\(\alpha\)\(\beta\) TCR and PEC-anti-CD4 antibodies. As shown in Fig. 7, the YAC-MHV3 or the L2-MHV3 virus did not induce significant alterations in CD4 subsets in vitro infected intrahepatic lymphoid cells. However, when CD8\(^+\) cells were depleted by cytotoxicity with anti-CD8 antibodies and complement, CD4\(^{\alpha\beta}\) TCRinter CD4\(^+\) cell percentages increased in YAC-MHV3-infected cells (P < 0.05) (Fig. 7B). Such increases were higher in L2-MHV3-infected cells after CD8\(^+\) cell depletion (P < 0.001). In addition, CD4\(^{\alpha\beta}\) TCR\(\text{high}\) cells slightly increased in YAC-MHV3-infected cells, while they decreased in L2-MHV3-infected cells (P < 0.05). Analysis of absolute numbers of such T cell subsets revealed that the relative percentage increase of CD4\(^{\alpha\beta}\) TCR\(\text{high}\) cells observed in control and infected cells reflected the depletion of CD8\(^{\alpha\beta}\) TCR\(\text{high}\) cells rather than a specific increase of CD4\(^{\alpha\beta}\) TCR\(\text{high}\) cells (results not shown).

DISCUSSION

In this paper, we report that the subclinical hepatitis induced by the attenuated YAC-MHV3 variant is related to low activation of intrahepatic CD4\(^+\) subsets, despite the presence of viral replication in the liver during the first days of infection, and to the recruitment of CD8\(^+\) cells, favoring viral elimination within 10 days pi.

Suppression of intrahepatic CD4\(^{\alpha\beta}\) TCRinter cells from C57BL/6 mice infected with the attenuated YAC-MHV3 virus is supported by many observations. First, intrahepatic lymphoid cells did not increase in YAC-MHV3-infected mice, in contrast to the increase ob-
served in pathogenic L2-MHV3-infected mice (21). Second, percentages of intrahepatic CD4$^\text{a}$– TCR$^\text{inter}$ and CD4$^\text{a}$– TCR$^\text{high}$ cells decreased in YAC-MHV3-infected mice, while they increased in pathogenic L2-MHV3-infected mice. Moreover, TCR$^\text{inter}$ or high LFA-1$^\text{high}$ subsets did not increase during the first days of infection with the YAC-MHV3 virus, as observed in L2-MHV3-infected mice (21). In addition, B220$^*$ or CD44$^+$ T cell subsets normally found in actively proliferating intrahepatic lymphoid cells (13, 16, 22) did not increase in attenuated YAC-MHV3-infected mice. Finally, CD8-depleted intrahepatic T lymphoid cells isolated from YAC-MHV3-infected mice could not be stimulated by lectins.

The role of anergized intrahepatic CD4$^+$ cell subsets in the hepatitis process may be evaluated in regard to the phenotypic changes of intrahepatic lymphoid cells in pathogenic L2-MHV3-infected mice. The decrease of intrahepatic NK-T cell subsets in both groups of infected mice suggests that this cell subset does not play a major role in viral elimination. We have previously shown that intrahepatic CD4$^+$ TCR$^\text{inter}$ or high LFA-1$^\text{high}$ increased in acute hepatitis induced by the pathogenic L2-MHV3 virus (21). In this work, we demonstrated that, in attenuated YAC-MHV3-infected mice, intrahepatic CD4$^+$ TCR$^\text{inter}$LFA-1$^\text{high}$ cells transiently decreased. In addition, these cells were anergized, since the partial stimulation of intrahepatic lymphoid cells from YAC-MHV3-infected mice was mainly due to CD8$^+$ cells, rather than CD4$^+$ cell subsets. Such a phenomenon did not occur in the spleen, suggesting that a specific intrahepatic mechanism occurs in the first days of infection, leading to a blockade of the maturation process or induction of a suppressive state of intrahepatic CD4$^+$ TCR$^\text{inter}$ cells comparable to that seen in immune tolerance.

Immune tolerance may be due to the unresponsiveness of resident T lymphocytes despite antigen pre-
The liver could be an elimination site for activated lymphocytes, as suggested by an increase of apoptotic liver-resident lymphocytes following antigenic stimulation or by their localization in hepatic sinusoids or in foci of degenerative hepatocytes caused by lymphocyte-thrombi-induced ischemia (22). No significant increase of apoptotic cells has been detected by a TUNEL test in intrahepatic lymphoid cells isolated from YAC-MHV3-infected mice (results not shown), suggesting that anergy observed in CD8-depleted cells, as soon as 3 days pi, was due not to an increase of activated lymphoid cells recruited from peripheral immune organs, but to an in situ cytokine-deprived suppression.

In contrast with other organs, leukocyte adhesion to intrahepatic endothelial cells (EC) does not require the expression of selectins but depends upon the endothelial expression of vascular adhesion protein 1 (29), LFA-1(CD11a)-CD54, and CD106-CD49 surface molecules (30). In addition, the number of leukocytes adhering to intrahepatic EC is controlled by a leukocyte–EC interactions and remains constant even if the total number or circulating leukocytes varies over time (30). However, EC are an important target for pathogenic L2-MHV3 replication but not for attenuated viral strains (25, 26). Other cytokines, such as IL-10 and prostanoids released by Kupffer cells, downregulate leukocyte adhesion to intrahepatic EC by decreasing surface expression of CD54 and CD116 (29) and then avoiding the recruitment of lymphoid cells and the immune-mediated liver damage by antigens from por-}

---

**FIG. 7.** Percentages of CD4αβ-TCR subsets in in vitro untreated (A) and CD8-depleted (B) intrahepatic lymphoid cells, subsequently uninfected (■) or infected with L2-MHV3 (□) and YAC-MHV3 (▲) viruses. Intrahepatic cells were isolated from C57BL/6 mice, treated with anti-CD8 antibodies and complement, infected with 0.1 to 1 m.o.i. of each virus, and then incubated for 24 h. Cells were then double labeled with FITC-anti-CD4 and PEC-anti-αβ-TCR antibodies and analyzed using a FACSscan cytometer. Lymphoid cells were gated according to FSC/SSC parameters, and numbers of cells were evaluated based on a total of 10,000 events recorded. Results are representative of three experiments. *P < 0.001; **P < 0.05.

sentation and activating cytokine production. The unresponsiveness of intrahepatic lymphocytes may result from several mechanisms. It has been proposed that an autocrine loop initiated by an interaction between lymphocytes and Kupffer cells can cause CD4+ activation and IFN-γ production, which in turn may induce NO release by Kupffer cells to suppress T cell proliferation (23, 24). Kupffer cells are an important target for pathogenic L2-MHV3 replication in the liver (25, 26), suggesting that this proposed mechanism would be altered during viral infection. YAC-MHV3 replication was lower in macrophages than that produced by pathogenic L2-MHV3 infection (27), suggesting that the tolerance, which is under control by Kupffer cells, would not be disturbed in YAC-MHV3-infected mice. Moreover, the production of IFN-α, tumor necrosis factor-α, or prostaglandin E2 (PGE2) by Kupffer cells could also be responsible for the decreased proliferative response of hepatic T cells (23, 24). In vivo treatment of attenuated YAC-MHV3-infected mice with a PGE2 inhibitor, such as indomethacin, did not increase the hepatitis severity and percentages of intrahepatic activated CD4+ TCR+ or highLFA-1+ cells (results not shown), suggesting that suppression of those lymphocytes is not under the control of PGE2. In addition, NK-T cells are known to be high producers of IL-4, favoring the stimulation of Th2 cells and production of cytokines involved in suppression of the Th1 response, such as that seen in immune tolerance (28). Since NK-T cells decreased in liver from both infected groups of mice, it is speculated that a decrease of Th2-dependent cytokines favors the activation of Th1 cells in both groups of infected mice. However, this mechanism may partially explain the activation of intrahepatic T cell subsets observed in L2-MHV3-infected mice (21) but cannot support the decrease of CD4+ cell subsets in YAC-MHV3-infected mice. In addition, the CD4+ belonging to the Th1 phenotype or NK cells can produce IFN-γ, which in turn is able to control viral replication. Preliminary in vitro experiments suggested that, in contrast to the L2-MHV3 virus, the YAC-MHV3 variant cannot replicate in the presence of IFN-γ.
On the other hand, the higher expression of LFA-1 molecules on intrahepatic TCR\textsuperscript{\text{inter}} cells may favor the binding of lymphocytes to some hepatic cells expressing a high level of ICAM-1. It is speculated that suppression of CD4 TCR\textsuperscript{\text{inter}}LFA-1\textsuperscript{\text{high}} cells, as seen in YAC-MHV3-infected mice, favors a down-regulation of ICAM-1 expression in hepatocytes in impairing production of cytokines by these cells, thus avoiding the binding of cytotoxic cells to hepatocytes. The decrease in T cells expressing high levels of LFA-1 would also be protective against destruction of the EC barrier by avoiding exposure of the underlying hepatocytes to further attack by cytotoxic cells. This hypothesis is supported by the fact that intrahepatic T cell subsets cannot be stimulated by the mitogen and that intragraft lymphoid cells from attenuated YAC-MHV3-infected mice did not express activation markers, such as CD44 or CD45R (B220). This mechanism has been previously demonstrated in the model of Con A-induced hepatitis in which the fulminant disease was mediated by activated CD4 T lymphocytes following their contact with hepatocyte-bound Con A (33, 34). In this situation, hepatic tolerance may be broken and tissue damages may result from the action of T cells activated by a liver microenvironment that has previously been conditioned by a microbial infection.

In this work, we have also observed that intrahepatic CD8\textsuperscript{T} cells are not anergic and may act as protective cells favoring viral elimination. Such a protective role of intrahepatic CD8 T cells has been reported in the hepatitis induced by Listeria monocytogenes, in which adoptive transfer of splenic CD4\textsuperscript{T} T cells alone exacerbated the disease, while bacterial clearance was mediated by cytotoxic CD8\textsuperscript{T} cells (35). The percentage increase of intrahepatic CD8\textsuperscript{T} cells observed in the YAC-MHV3-infected mice may result either from an in situ stimulation of intrahepatic resident CD8\textsuperscript{T} cells or from a recruitment of circulating lymphocytes. The fact that percentages of CD8\textsuperscript{T} T cells transiently decreased in the liver while splenic CD8\textsuperscript{T} cells increased indicates that a peripheral stimulation of splenic CD8\textsuperscript{T} cells occurs before the increase of intrahepatic CD8\textsuperscript{T} cells. The increase of intrahepatic T cell subsets expressing a lower level of LFA-1 antigen, such as that observed in splenic cells (14, 21), suggests that intrahepatic CD8\textsuperscript{T} cells are recruited from the blood. However, the recruitment of CD8\textsuperscript{T} cells requires that there may be no major intrahepatic vascular disorders induced by the viral infection, such as demonstrated in pathogenic L2-MHV3 infection (36). We can thus postulate that attenuated YAC-MHV3 infection in liver does not involve intravascular coagulation, as demonstrated by nonextensive pathological damages with perivascular lymphoid cells (8), thus enabling the recruitment of circulating activated CD8\textsuperscript{T} cells. This hypothesis is also supported by the observation of lower levels of CD8\textsuperscript{T} cells and the strong anergy observed in in vivo lectin-stimulated intrahepatic lymphoid cells from L2-MHV3-infected mice.

Interestingly, in vitro L2-MHV3 infection of intrahepatic lymphoid cells revealed that intrahepatic CD4 TCR\textsuperscript{\text{inter}} or high cell subsets increased when CD8 cells were depleted, suggesting that CD8 cells may prevent the activation of CD4 cell subsets. However, depletion of CD8 cells in YAC-MHV3-infected intrahepatic lymphoid cells did not provoke a strong increase of CD4 subsets, indicating that an increase of CD4 cell subsets depends on both the pathogenic properties of the virus strain and the absence of CD8\textsuperscript{T} cells.

We can conclude that the attenuated phenotype of the YAC-MHV3 variant is related to recruitment of cytotoxic CD8\textsuperscript{T} cells produced in peripheral lymphoid organs, such as the spleen, allowing the elimination of infected cells in the liver without breaking hepatic immune tolerance mechanisms. Further work is in progress to identify the virally mediated cell dysfunctions involved in the breakdown of tolerance mechanisms induced during the L2-MHV3 infection and in the recruitment of peripheral CD8\textsuperscript{T} cells in YAC-MHV3-infected mice.

**ACKNOWLEDGMENTS**

This work was supported by grants from NSERC-Canada and the Liver Canadian Foundation. The authors thank Mr. Christophe Dugrè for technical assistance and Mrs. Diane Décarie and Mr. Dimitri Prontzos for revising the manuscript.

**REFERENCES**

1. Byrne, J. A., and Oldstone, M. B. A., Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: Clearance of virus in vivo. J. Virol. 51, 682–686, 1984.
2. Fung-Leung, W. P., Kundig, T. M., Zingermakel, R. M., and Mak, T. W., Immune response against lymphocytic choriomeningitis virus infection without CD8 expression. J. Exp. Med. 174, 1425–1429, 1991.
3. Reddehase, M. J., Mutter, W., Munch, K., Burhing, H. J., and Koszinowski, U. H., CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61, 3102–3108, 1987.
4. Chiari, F. V., Ferrari, C., and Mondelli, M. U., Hepatitis B structure and biology. Microb. Pathog. 6, 311–325, 1989.
5. Missal, G., Bertoni, R., Lamonaca, Valle, A., Massari, M., Mori, C., Rumi, C., Houghton, M., Fiaccadori, F., and Ferrari, C., Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98, 706–714, 1996.
6. Wege, H., Siddel, S., Sturman, M., and TerMeulen, V., The biology and pathogenesis of coronaviruses. Curr. Top. Microbiol. Immunol. 99, 165–192, 1982.
7. Le Prévost, C., Levy-Leblond, B., Virelizier, J. L., and Dupuy, J. M., Immunopathology of mouse hepatitis virus type 3 infection. I. Role of humoral and cell-mediated immunity in resistance mechanism. J. Immunol. 134, 221–225, 1975.
8. Lamontagne, L., Descoteaux, J. P., and Jolicoeur, P., T and B lymphotropisms of mouse hepatitis virus 3 correlate with viral pathogenicity. J. Immunol. 142, 4458–4465, 1989.

9. Jolicoeur, P., and Lamontagne, L., Mouse hepatitis virus 3 pathogenicity expressed by a lytic viral infection in bone marrow 14.8+μ+ B lymphocyte subpopulations. J. Immunol. 143, 3722–3730, 1989.

10. Lamontagne, L., and Jolicoeur, P., Mouse hepatitis virus 3 thymic cell interactions correlating with viral pathogenicity. J. Immunol. 146, 3152–3159, 1991.

11. Lamontagne, L., and Dupuy, J. M., Persistent infection with mouse hepatitis virus 3 in mouse lymphoid cell lines. Infect. Immun. 44, 716–723, 1984.

12. Seki, S., Abo, T., Ohteki, T., Sugiiura, K., and Kumagai, K., Unusual αβ-T cells expanded in autoimmune Ipr mice are probably a counterpart of normal T cells in the liver. J. Immunol. 147, 1214–1221, 1991.

13. Ohteki, T., Okuyama, R., Seki, S., Abo, T., Sugiiura, K., Kumusumi, A., Ohmori, T., Watanabe, H., and Kumagai, K., Age-dependent increase in extrathymic T cells in the liver and their appearance in the periphery of older mice. J. Immunol. 149, 1562–1570, 1992.

14. Watanabe, H., Ohtsuka, K., Kimura, M., Ikarashi, Y., Ohmori, K., Kumusumi, A., Ohteki, T., Seki, S., and Abo, T., Similarities and differences between extrathymic T cells residing in mouse liver and intestine. Cell. Immunol. 153, 52–66, 1992.

15. Ohteki, T., Seki, S., Abo, T., and Kumagai, K., Liver is a possible site for the proliferation of abnormal CD3 CD4 CD8 double-negative lymphocyte in autoimmune MRL Ipr/Ipr mice. J. Exp. Med. 172, 7–12, 1990.

16. Hashimoto, W., Takeda, K., Anzai, R., Ogasawara, K., Sakiha, H., Sugiiura, K., Seki, S., and Kumagai, K., Cytotoxic NK1.1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154, 4333–4340, 1995.

17. Matsumoto, Y., Emoto, M., Usami, J., Maeda, K., and Yoshikai, Y., A protective role of extrathymic αβ TCR cells in the liver in primary salmonellosis. Immunology 81, 8–14, 1994.

18. Emoto, M., Emoto, Y., and Kaufmann, S. H. E., Interleukin-4 producing CD4 NK1.1 TCRαβ intermediate liver lymphocytes are down-regulated by Listeria monocytogenes. Eur. J. Immunol. 25, 3321–3325, 1996.

19. Bhawardj, V., Kanawaga, O., Swanson, P. E., and Unanue, E. R., Chronic Listeria infection in SCID mice: Requirements for the carrier state and the dual role of T cells in transferring protection or suppression. J. Immunol. 160, 376–384, 1998.

20. Lamontagne, L., Massicotte, E., and Page, C., Mouse hepatitis viral infection induces an extrathymic differentiation of the specific intrahepatic αβ-TCR intermediate LFA-1high T-cell population. Immunology 90, 402–411, 1997.

21. Huang, L., Sze, C., and Crispe, N., Proliferation and apoptosis of B220CD4 CD8 TCRαβ intermediate in the liver of normal adult mice: Implication for Ipr pathogenesis. Int. Immunol. 6, 553–540, 1994.

22. Roland, C. R., Walp, L., Stack, R. M., and Flye, M. W., Outcome of Kupffer cell antigen presentation to a cloned murine Th1 lymphocyte depends on the inducibility of nitric oxide synthase by IFN-gamma. J. Immunol. 153, 5453–5364, 1994.

23. Callery, M. P., Mangino, M. J., and Flye, M. W., Arginine-specific suppression of mixed lymphocyte culture reactivity by Kupffer cells—a basis for portal venous tolerance. Transplantation 51, 1076–1080, 1991.

24. Pereira, C. A., Steffan, A. M., and Kirn, A., Interaction between mouse hepatitis virus and primary cultures of Kupffer and endothelial liver cells from resistant and susceptible inbred mouse strains. J. Gen. Virol. 65, 1617–1620, 1984.

25. Martin, J. P., Chen, W., Koothren, F., and Pereira, C. A., The virulence of mouse hepatitis virus 3, as evidenced by permissiveness of cultured hepatic cells toward escape mutants. Res. Virol. 145, 297–302, 1994.

26. Lamontagne, L., Decarie, D., and Dupuy, J. M., Host cell resistance to mouse hepatitis virus type 3 is expressed in vitro in macrophages and lymphocytes. Viral Immunol. 2, 37–45, 1989.

27. Yashimoto, T., and Paul, W. E., CD4+ NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179, 1285–1295, 1994.

28. McNab, G., Reeves, J. L., Salmi, M., Hubshnerr, S., J. alkanen, S., and Adams, D. H., Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastroenterology 110, 522–528, 1996.

29. Wong, J., Johnston, B., Lee, S. S., Bullard, D. C., Smith, C. V., Beaudet, A. L., and Kubes, P., A minimal role for inductin in the recuitment of leukocytes into the inflammed liver microvasculature. J. Clin. Invest. 99, 2782–2790, 1997.

30. Knolle, P. A., Uhrig, A., Hegenbarth, S., Loser, E., Schmitt, E., Gerken, G., and Lohse, A. W., IL-10 down-regulates T cell activation by antigen presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin. Exp. Immunol. 114, 427–433, 1998.

31. Knolle, P., Schlaak, J., Uhrig, A., Kempf, P., Meyer zum Buschenfeld, K. H., and Gerken, G., Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 22, 226–229, 1995.

32. Tieg, G., Hentscher, J., and Wendel, A., A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90, 196–203, 1992.

33. Gantner, F., Leist, M., Lohse, A. W., Gerken, G., and Leist, M., A T cell-dependent experimental liver injury in mice: The role of tumor necrosis factor. Hepatology 21, 190–198, 1995.

34. Levy, G. A., Leibowitz, J. L., and Edgington, T. S., Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J. Exp. Med. 154, 1150–1163, 1981.